Loading
Cancer, Lipids, and Metabolism / Cancer, Stress, Anesthesia, and Immune Response · Review
Discover Medicine · September 7, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes observational and meta-analytic evidence on three common comedications in ICI-treated cancer patients. Statins appear associated with improved ICI efficacy (pooled HR for OS 0.8), PPIs consistently reduce efficacy (pooled HR ~1.18), and baseline corticosteroids are associated with worse outcomes (HR ~1.54), whereas corticosteroids used to treat immune-related adverse events do not appear to reduce survival benefit. The authors recommend reducing unnecessary PPIs, rationalizing baseline corticosteroid use, and continuing statins if clinically required, but note that prospective trials are needed to validate these relationships.
Narrative review with synthesis of published meta-analyses and observational cohort studies. Aging cancer patients with polypharmacy receiving immune checkpoint inhibitors and concomitant statin, proton pump inhibitor, and/or systemic corticosteroid therapy.. Intervention: Concomitant statin, proton pump inhibitor, or systemic corticosteroid use during ICI therapy.. Compared with: No such medications or baseline comparison cohorts within observational studies (comparators implicit in published meta-analyses)..
Statin use associated with improved ICI effectiveness: pooled HR for OS 0.8 (95% CI 0.71–0.92) PPI use consistently reduces ICI efficacy with dose-dependent gut microbiome dysbiosis: pooled HR ~1.18 Baseline corticosteroid use (≥10 mg prednisone equivalent) negatively correlated with long-term outcomes: HR ~1.54
Baseline corticosteroid effect is situation-specific; therapeutic use for irAEs does not appear harmful, suggesting complex dose and timing effects not fully characterized. Therapeutic corticosteroids for immune-related adverse events do not appear to reduce long-term survival advantage
Clinicians should consider deprioritizing unnecessary PPIs in patients on ICI therapy, rationalizing baseline corticosteroid prescriptions, and continuing statins if clinically indicated. However, these recommendations rest on observational evidence subject to confounding, and prospective trials are needed before confident practice changes.
A narrative review synthesizing observational and meta-analytic evidence on drug–ICI interactions, offering clinical recommendations on statin, PPI, and corticosteroid use during checkpoint inhibitor therapy, but not reporting new primary data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider deprioritizing unnecessary PPIs in patients on ICI therapy, rationalizing baseline corticosteroid prescriptions, and continuing statins if clinically indicated. However, these recommendations rest on observational evidence subject to confounding, and prospective trials are needed before confident practice changes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Immune checkpoint inhibitors (ICI) are increasingly and highly used in aging cancer patients with polypharmacy. The common comedications, such as statins, proton pump inhibitors (PPIs), and corticosteroids, have the potential to interact with ICIs and alter their effectiveness and toxicity, although a synthesis of this evidence is not offered in detail. Objective To conduct a narrative review and summarize available preclinical and clinical evidence on the impact that concomitant statin, PPI, and systemic corticosteroids had on the (overall/progression-free survival) and safety (immune-related adverse events) of ICI therapy. Methodology We conducted a narrative review on the base of systematic search in PubMed/MEDLINE, Embase, and Web of Science (January 2020–April 2026). The subject of the thematic synthesis of literature on interactions between ICIs (anti-PD-1/PD-L1, anti-CTLA-4) and the three classes of drugs. All quantitative estimates are obtained by means of the published meta-analyses and cohort analyses, no additional pool analysis was conducted. Key findings According to published meta-analyses reports, statin use is associated with improved ICI effectiveness in some studies, because of their impact on antitumor immunity through mevalonate pathway inhibition (pooled HR for OS: 0.8; 95% CI: 0.71–0.92). It has been repeatedly shown in multiple observational studies that PPIs consistently reduce efficacy of ICIs because of their dose-dependent gut microbiome dysbiosis effect which becomes especially harmful when patients exceed high usage before ICI treatment (pooled HR ~ 1.18). The relationship of corticosteroids and ICI outcome seems situation-specific based on observational data: baseline use (≥ 10 mg prednisone equivalent), by contrast, has been indicated to be negatively correlated with long-term outcomes in retrospective cohorts (HR ~ 1.54), whereas therapeutic administration for immune-related side effects does not seem to reduce long-term survival advantage in reported studies. Conclusion Observational studies indicated that concomitant medications have significant effect on ICI outcomes due to pharmacodynamics interaction. Reducing the prescription of needless PPIs during ICI therapy, thorough rationale for baseline corticosteroids and statin continuation (if clinically required) may be justified, although prospective studies should pay more attention to validate relationships. Although preclinical research and observational data provide the majority of the evidence, concurrent drugs may also impact the effectiveness of ICIs through pharmacodynamic processes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.